1 | Page
NR 567 FINAL EXAM – ADVANCED
PHARMACOLOGY FOR THE AGACNP
COMPREHENSIVE QUESTION PRACTICE
TEST WITH VERIFIED ANSWERS AND
RATIONALES 2026 UPDATE –
CHAMBERLAIN UNIVERSITY
PART 1: PHARMACOKINETICS AND PHARMACODYNAMICS
Question 1
Which of the following medications should be given to patients
presenting to the emergency department with an altered level of
consciousness, seizures, or both, if a concern of Wernicke-Korsakoff
syndrome exists?
A) Folate (Folic acid)
B) Chlordiazepoxide (Librium)
C) Thiamine (Vitamin B1)
D) Lorazepam (Ativan)
Verified Answer: C
Rationale: Thiamine (Vitamin B1) is crucial in treating Wernicke-
Korsakoff syndrome as it addresses the underlying thiamine deficiency.
Wernicke-Korsakoff syndrome is a neurological disorder primarily
,2 | Page
caused by thiamine deficiency, often associated with chronic alcoholism.
Wernicke's encephalopathy is a medical emergency requiring immediate
thiamine administration. Early recognition and treatment with thiamine
can improve outcomes and prevent further complications .
Question 2
A patient with severe hepatic failure will most likely have which change
in drug pharmacokinetics?
A) Increased renal excretion
B) Decreased oral absorption
C) Reduced metabolism and prolonged half-life of hepatically cleared
drugs
D) Increased protein binding
Verified Answer: C
Rationale: Hepatic failure reduces the metabolism of drugs cleared by
the liver, increasing their half-life and drug exposure. This has
significant clinical implications for dosing medications in patients with
liver disease. The AGACNP must adjust doses accordingly to avoid
toxicity .
Question 3
What is the primary determinant of a drug's volume of distribution (Vd)?
A) Protein binding
B) Renal clearance
C) Lipid solubility and tissue binding
,3 | Page
D) Hepatic metabolism
Verified Answer: C
Rationale: Volume of distribution reflects how extensively a drug
distributes into tissues. Lipophilic drugs with high tissue binding have
larger Vd, whereas hydrophilic drugs that remain in the vascular
compartment have smaller Vd. Protein binding and renal clearance
influence other pharmacokinetic parameters but are not the primary
determinants of Vd .
Question 4
A patient on warfarin has an INR of 1.5. What is the appropriate action?
A) Increase the warfarin dose
B) Decrease the warfarin dose
C) Administer vitamin K
D) Hold the warfarin dose
Verified Answer: A
Rationale: An INR of 1.5 is subtherapeutic for most indications requiring
warfarin therapy. The appropriate action is to increase the warfarin dose
to achieve the target INR range, typically 2.0-3.0 for most indications.
Vitamin K is used for reversal of warfarin, not for dose adjustment .
Question 5
Which laboratory test is used to monitor unfractionated heparin therapy?
, 4 | Page
A) Prothrombin time (PT) / INR
B) Activated partial thromboplastin time (aPTT)
C) Thrombin time
D) D-dimer
Verified Answer: B
Rationale: aPTT is the standard test used to monitor unfractionated
heparin therapy. The therapeutic goal is usually 1.5-2.5 times the normal
control value. PT/INR is used to monitor warfarin therapy. D-dimer is
used to assess for clot formation .
Question 6
Which of the following statements best describes the mechanism of
action of warfarin?
A) Direct thrombin inhibition
B) Blockade of vitamin K-dependent carboxylation of clotting factors II,
VII, IX, and X
C) Inhibition of factor Xa
D) Activation of antithrombin III
Verified Answer: B
Rationale: Warfarin is a vitamin K antagonist that prevents the gamma-
carboxylation of clotting factors II, VII, IX, and X, leading to the
production of inactive clotting factors. This is a different mechanism
than direct thrombin inhibitors (dabigatran), factor Xa inhibitors
(rivaroxaban, apixaban), and heparin (activates antithrombin III) .
NR 567 FINAL EXAM – ADVANCED
PHARMACOLOGY FOR THE AGACNP
COMPREHENSIVE QUESTION PRACTICE
TEST WITH VERIFIED ANSWERS AND
RATIONALES 2026 UPDATE –
CHAMBERLAIN UNIVERSITY
PART 1: PHARMACOKINETICS AND PHARMACODYNAMICS
Question 1
Which of the following medications should be given to patients
presenting to the emergency department with an altered level of
consciousness, seizures, or both, if a concern of Wernicke-Korsakoff
syndrome exists?
A) Folate (Folic acid)
B) Chlordiazepoxide (Librium)
C) Thiamine (Vitamin B1)
D) Lorazepam (Ativan)
Verified Answer: C
Rationale: Thiamine (Vitamin B1) is crucial in treating Wernicke-
Korsakoff syndrome as it addresses the underlying thiamine deficiency.
Wernicke-Korsakoff syndrome is a neurological disorder primarily
,2 | Page
caused by thiamine deficiency, often associated with chronic alcoholism.
Wernicke's encephalopathy is a medical emergency requiring immediate
thiamine administration. Early recognition and treatment with thiamine
can improve outcomes and prevent further complications .
Question 2
A patient with severe hepatic failure will most likely have which change
in drug pharmacokinetics?
A) Increased renal excretion
B) Decreased oral absorption
C) Reduced metabolism and prolonged half-life of hepatically cleared
drugs
D) Increased protein binding
Verified Answer: C
Rationale: Hepatic failure reduces the metabolism of drugs cleared by
the liver, increasing their half-life and drug exposure. This has
significant clinical implications for dosing medications in patients with
liver disease. The AGACNP must adjust doses accordingly to avoid
toxicity .
Question 3
What is the primary determinant of a drug's volume of distribution (Vd)?
A) Protein binding
B) Renal clearance
C) Lipid solubility and tissue binding
,3 | Page
D) Hepatic metabolism
Verified Answer: C
Rationale: Volume of distribution reflects how extensively a drug
distributes into tissues. Lipophilic drugs with high tissue binding have
larger Vd, whereas hydrophilic drugs that remain in the vascular
compartment have smaller Vd. Protein binding and renal clearance
influence other pharmacokinetic parameters but are not the primary
determinants of Vd .
Question 4
A patient on warfarin has an INR of 1.5. What is the appropriate action?
A) Increase the warfarin dose
B) Decrease the warfarin dose
C) Administer vitamin K
D) Hold the warfarin dose
Verified Answer: A
Rationale: An INR of 1.5 is subtherapeutic for most indications requiring
warfarin therapy. The appropriate action is to increase the warfarin dose
to achieve the target INR range, typically 2.0-3.0 for most indications.
Vitamin K is used for reversal of warfarin, not for dose adjustment .
Question 5
Which laboratory test is used to monitor unfractionated heparin therapy?
, 4 | Page
A) Prothrombin time (PT) / INR
B) Activated partial thromboplastin time (aPTT)
C) Thrombin time
D) D-dimer
Verified Answer: B
Rationale: aPTT is the standard test used to monitor unfractionated
heparin therapy. The therapeutic goal is usually 1.5-2.5 times the normal
control value. PT/INR is used to monitor warfarin therapy. D-dimer is
used to assess for clot formation .
Question 6
Which of the following statements best describes the mechanism of
action of warfarin?
A) Direct thrombin inhibition
B) Blockade of vitamin K-dependent carboxylation of clotting factors II,
VII, IX, and X
C) Inhibition of factor Xa
D) Activation of antithrombin III
Verified Answer: B
Rationale: Warfarin is a vitamin K antagonist that prevents the gamma-
carboxylation of clotting factors II, VII, IX, and X, leading to the
production of inactive clotting factors. This is a different mechanism
than direct thrombin inhibitors (dabigatran), factor Xa inhibitors
(rivaroxaban, apixaban), and heparin (activates antithrombin III) .
